AstraZeneca agreed to pay Dizal Pharmaceutical up to $1.5 billion for exclusive global rights to develop and commercialize Zegfrovy (sunvozertinib). The deal secures AZ’s role in a targeted EGFR exon 20 insertion program that Dizal is advancing into first-line NSCLC after positive Phase III data. In WU-KONG28 (NCT05668988), Zegfrovy delivered a median progression-free survival of 10.3 months versus 7.5 months with platinum-doublet chemotherapy. Dizal also reported BICR-assessed best objective response rate of 68.1% versus 35.4% and median duration of response of 11.2 versus 7.1 months. Dizal has filed supplemental NDAs with the FDA and China’s Center for Drug Evaluation for the first-line indication, with Breakthrough Therapy designations. The agreement follows AstraZeneca’s existing EGFR presence led by Tagrisso and reflects intensified competition in EGFR-mutant lung cancer with oral targeted options. For investors and partners, the headline risk is whether label expansion timing and adoption match the clinical effect size; the key upside is building a global commercial platform for a differentiating, single-agent oral regimen in a genetically defined market.